Navigation Links
Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Date:11/18/2009

e further enhanced by the fact that Biothionol is already available for a different indication. We therefore expect an accelerated regulatory path to proof of clinical concept," said Guy Malchi, head of corporate development for Champions.

This is the third compound to be in-licensed into Champions' rapidly growing pipeline of oncology compounds. Recently, Champions announced the licensing of TAR-1, a single-chain antibody fragment, from Ramot at Tel Aviv University.

"We are excited to work with Champions' experienced scientific team to translate these promising early findings towards a meaningful clinical program by leveraging Champions' preclinical platform," said Demetrios Braddock, M.D., Ph.D., Associate Professor of Pathology in Yale School of Medicine and the Yale inventor of the licensed technology.

"It is gratifying to see the work of Southern Research and Yale scientists being channeled in this way, and to hopefully lead to the development of another new drug for cancer patients," said Nancy M. Gray, Ph.D., vice president of Corporate Development for Southern Research Institute. "This licensing opportunity with the Champions team fits quite well within Southern Research's own mission of conducting basic and translational research that ultimately leads to the approval of a new drug."

The work was funded, in part, by the Yale Clinical and Translational Science Award (CTSA) grant from the National Center for Research Resources at the National Institutes of Health.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM))
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
2. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
5. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
6. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
7. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
8. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
9. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
10. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . ... have demonstrated a new kind of building block for ... chips could be based on three-dimensional arrangements of nanometer-scale ... of the semiconductor industry CMOS fabrication of silicon ... collaborators at the University of Notre Dame are exploring ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Willebrords 1 and Bart Moyson 2 , ... Development, a division of Janssen Pharmaceutica N.V., Laboratory of Virology, Beerse, Belgium ... Life Sciences Benelux NV, Teralfene, Belgium , ... of this paper is to report the performance obtained by dispensing 1μL organic ...
... Jeff Cunningham and Lynn Jordan ... Inc., Applications Laboratory, Hopkinton, Massachusetts, USA , ... The ability to continuously dispense reagents across multi-well plates ... high throughput laboratories. Equally important, however, is the precision that can ...
... , Bruce R. Conklin 1 , Laurence L. Brunton ... Anne T. Ferguson 4 , 1 Gladstone ... Pharmacology 2 and Medicine 3 , ... 4 Molecular Devices Corp., 1311 Orleans Drive, Sunnyvale, CA 94089, , , ...
Cached Biology Technology:96 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3Sciclone ALH Bulk Dispense Precision Testing 2Gq-coupled Receptor Assays Using FLEXstation 2Gq-coupled Receptor Assays Using FLEXstation 3Gq-coupled Receptor Assays Using FLEXstation 4Gq-coupled Receptor Assays Using FLEXstation 5Gq-coupled Receptor Assays Using FLEXstation 6Gq-coupled Receptor Assays Using FLEXstation 7
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Risky metabolism 2
... Can the hold that Intelligent Design theorists have in ... a leading American evolutionist, makes the case for Darwin ... Reporting from the front lines of America's struggle over ... (University College London) on 16th November. , In his ...
... inoculate everyone in the United States could be grown ... plants, a University of Central Florida molecular biologist has ... UCF professor Henry Daniell's laboratory through the genetic engineering ... later by National Institutes of Health researchers. The results ...
... special green-algae gene into neurons of the tiny, ... to elicit specific behavioral responses by simply illuminating ... way for better understanding of how neurons communicate ... behavior in intact, living organisms. Generally speaking, detailed ...
Cached Biology News:'Creationism is not science' ?making the case for Darwin at UCL 2Effective, safe anthrax vaccine can be grown in tobacco plants 2Effective, safe anthrax vaccine can be grown in tobacco plants 3Algal protein in worm neurons allows remote control of behavior by light 2
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: